×

In ‘landmark’ approval, FDA OKs Ocrevus for kids 10 and older with RRMS

In ‘landmark’ approval, FDA OKs Ocrevus for kids 10 and older with RRMS

Comments Off on In ‘landmark’ approval, FDA OKs Ocrevus for kids 10 and older with RRMS

An adult holds the bandaged hand of a child in a hospital bed receiving an infusion, while the youngster clutches a teddy bear with the other hand.

The U.S. Food and Drug Administration (FDA) has approved the infusion therapy Ocrevus (ocrelizumab) for treating children with relapsing-remitting multiple sclerosis (RRMS) who are ages 10 and older and weigh at least 55 pounds (25 kg). The approval makes Ocrevus the second-ever therapy to win formal FDA approval for this indication, according to its developer […]

The post In ‘landmark’ approval, FDA OKs Ocrevus for kids 10 and older with RRMS appeared first on Multiple Sclerosis News Today.

Source: multiplesclerosisnewstoday.com